Similar Papers

Paper Title
Journal
Date
Author
Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients
Anthony R Mato ...
Blood | VOL. 132
Anthony R Mato, et. al.Anthony R Mato ...
29 Nov 2018
Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas‘
Francesca Romana Mauro ...
Blood | VOL. 136
Francesca Romana Mauro, et. al.Francesca Romana Mauro ...
05 Nov 2020
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Alessandra Tedeschi ... Xavier C Badoux
Blood | VOL. 134
Alessandra Tedeschi, et. al.Alessandra Tedeschi ... Xavier C Badoux
13 Nov 2019
Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group
Charline Moulin ... Pierre Feugier
Blood | VOL. 134
Charline Moulin, et. al.Charline Moulin ... Pierre Feugier
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL.
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD.
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma.
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.